Twin Peaks Wealth Advisors LLC Purchases New Position in Johnson & Johnson (NYSE:JNJ)

Twin Peaks Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,289 shares of the company’s stock, valued at approximately $202,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Hibernia Wealth Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at about $27,000. FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson in the third quarter worth about $37,000. Tower View Wealth Management LLC raised its stake in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 165 shares during the last quarter. Creative Capital Management Investments LLC raised its stake in shares of Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after acquiring an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $48,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on JNJ. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Raymond James boosted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.31.

Insider Activity

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.4 %

Shares of NYSE JNJ opened at $157.96 on Thursday. The stock has a market cap of $380.65 billion, a P/E ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53. The firm has a 50 day moving average price of $158.76 and a 200 day moving average price of $156.69. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The firm had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.35 earnings per share. Analysts expect that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were issued a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.